Our Team
Pepdura is led by a distinguished team with decades of experience in pharmaceutical innovation and business leadership, reflecting a blend of strategic vision and scientific expertise. The team's collective accomplishments and dedication fuel Pepdura's mission to advance drug development and meet the evolving needs of patients globally. Complementing our internal expertise, Pepdura's extensive network includes renowned scientific and clinical advisors, as well as experienced Contract Research Organizations, all dedicated to excellence in preclinical development.
Kjell Stenberg
Chief Executive Officer
Kjell Stenberg, CEO has served at AstraZeneca Plc at different R&D management positions for 20 years followed by 10 years as AZ’s Global License Director Neurology. After AZ, he has funded, co-founded and managed biotech companies in Sweden, Denmark, Norway, Canada and Switzerland.; Combio A/S, CePeP AB, Orexo AB, ACQ Med AB, BioMS Medical Ltd, Medwell Capital, Accequa AB, Aptahem AB, Cyxone AB, Galecto Biotech A/S, Acctena AB, Novation Pharma, Notify Therapeutics A/S, Nodes Advisors.
​
He has been awarded the Scrips “Licensing Deal of the Year” in 2009 for the MS-peptide drug dirucotide with Eli Lilly.
Christian Gruber
Chief Scientific Officer
Christian Gruber, CSO is Associate Professor at the Medical University of Vienna (Austria). His research focus is the biological function, structure-activity relationship and pharmacological mechanism of nature-derived peptides targeting GPCRs. He won the EFMC Prize for a Young Medicinal Chemist in Academia by the European Federation for Medicinal Chemistry (2017) and the Heribert-Konzett Award by the Austrian Pharmacological Society (2013). He is member elect of the “Max-Bergmann-Kreis”, Associate Editor of the British Journal of Pharmacology and Editorial Board Member of the Journal of Medicinal Chemistry. He has published over 90 manuscripts and patent applications.